<DOC>
	<DOCNO>NCT01631643</DOCNO>
	<brief_summary>Evaluation clinical benefit One Touch VerioIQ system .</brief_summary>
	<brief_title>One Touch® Verio®IQ European Clinical Outcomes Study</brief_title>
	<detailed_description>Evaluation clinical benefit One Touch VerioIQ system . The system contain pattern alert technology come educational material ( Pattern guide ) provide additional support insight patient health care provider help make informed decision blood glucose management .</detailed_description>
	<criteria>male female least 18 80 year old ADA guideline FPG PPG appropriate A1C great equal 8.0 % less equal 10.5 % lab A1C great equal 8.0 % last 612mths Diagnosed type 1 2 least last 1 year stable dose OADs least 3mths prior screen willingness test 7 BGM test per day willing remain therapy baseline ( MDI ) duration study unlikely compliant study procedure currently use One Touch VerioIQ Is fix dos insulin MDI therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Blood glucose monitor</keyword>
	<keyword>Pattern management</keyword>
	<keyword>Pattern guide</keyword>
	<keyword>Education</keyword>
</DOC>